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Abstract 
Hemolytic uremic syndrome (HUS) is a rare, life threatening disease characterized 
by thrombocytopenia, microangiopathic hemolytic anemia and acute renal failure. The 
atypical form of HUS (aHUS), representing 5-10% of cases, lacks the association with 
infection by Shiga toxin producing E. coli strains that characterizes the commonest clinical 
presentation of HUS. In the majority of aHUS cases the disease results from the 
complement-mediated damage to the microvascular endothelium due to inherited defects in 
complement genes or autoantibodies against complement regulatory proteins. Incomplete 
penetrance of aHUS in carriers of mutations is common to all aHUS-associated 
complement genes and it is now established that the overall genetic predisposition to aHUS 
of an individual results from the combination of different inherited factors. Moreover, the 
patient’s genotype influences the clinical evolution, the response to plasma therapies and 
the recurrence after transplantation. Here we describe the genetic component of aHUS, the 
lessons that we have learned from the functional characterization of the aHUS-associated 
mutations and the benefits of a comprehensive genetic analysis of the patients. 
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Since the early 1980’s, atypical hemolytic uremic syndrome (aHUS) has been 
associated with complement abnormalities and in particular with activation of the 
alternative pathway. It was, however, the genome-wide linkage analysis performed in 1998 
by Warwicker et al. which formally established the relationship between aHUS and the 
RCA (regulator of complement activation) gene cluster at 1q32 encoding factor H and 
other complement regulatory proteins (1). These findings triggered a series of decisive 
studies that delineated the genetic predisposition to aHUS and revealed its pathogenic 
mechanisms, changing the earlier perception that aHUS was a pathology related to 
hypocomplementemia (lack of complement) to the realization that aHUS is a disorder 
involving tissue damage caused by dysregulated complement activation (2-8). 
Most aHUS cases have a strong genetic component involving mutations (normally 
in heterozygosis) and polymorphisms in the genes encoding the complement regulatory 
proteins factor H (CFH) (1-3, 5, 6, 9), membrane cofactor protein (MCP) (10-12) and 
factor I (CFI) (13, 14), and in the genes encoding the complement components factor B 
(CFB) (15) and C3 (C3) (16). In addition, genes in the coagulation pathway like 
thrombomodulin (THBD), which functions as a cofactor for thrombin to reduce blood 
coagulation and also regulates factor I-mediated C3b inactivation, and more recently 
plasminogen (PLG), a zymogen that is converted into plasmin and plays an important role 
in fibrinolysis, have also been implicated in aHUS (17, 18). Finally, it has recently been 
found that a subgroup of aHUS patients with a very early onset (<1 year of age) carry 
mutations in the gene encoding diacylglycerol kinase-ε (DGKE), a intracellular protein 
implicated in podocyte homeostasis and in modulating protein kinase C activity in 
endothelial cells and platelets (19, 20). A summary of the mutations in all these aHUS-
associated genes is depicted in Figures 1, 2 and 3 and Table 1. 
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Complement regulators in aHUS 
Missense mutations in the C-terminus of factor H, a region that is critical to the 
capacity of the protein to bind cell surfaces and control local activation of complement, are 
prototypical of aHUS (21). CFH mutations are also the most prevalent genetic alteration, 
representing approximately 25% of the cases in all aHUS cohorts. Carriers of the C-
terminal mutations express factor H molecules with a limited capacity to bind and protect 
cells from complement lysis (4, 5, 7, 8). Interestingly C-terminal factor H mutations do not 
alter complement regulation in plasma and carriers of these mutations have normal levels 
of C3 in plasma. These findings are in agreement with the identification of aHUS-
associated loss-of-function mutations in MCP and CFI for the reason that the MCP and 
factor I mutations also lead to an impaired protection of host cells from complement lysis 
without affecting significantly complement regulation in plasma (22). CFH mutations that 
lead to partial factor H deficiencies in aHUS patients also fit these ideas, as it is known for 
a long time that decreased levels of factor H affect primarily the complement regulation on 
surfaces (23).  
The combination of both, an active complement system in plasma and a defective 
protection of cellular surfaces portrays aHUS as a situation of “autolesion” caused by the 
uncontrolled activation of complement on cell surfaces. By decreasing concentrations of 
factor H or factor I in plasma, or MCP on cell surfaces, aHUS-associated mutations 
predispose to disease. In a situation that triggers complement activation, carriers of aHUS 
predisposing factors cannot control deposition and amplification of C3b on the 
microvasculature cellular surfaces, which results in tissue damage and destruction. The 
surface dysregulation that characterizes aHUS is clearly distinct from the lack of 
complement regulation in plasma, leading to complete C3 consumption and severe 
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hypocomplementemia that is typical, for example, of dense deposit disease (DDD) patients. 
In this respect, it is now widely accepted that the differential association of mutations and 
polymorphisms in factor H and other complement proteins with aHUS and other 
glomerulopathies, depending on whether they cause surface or fluid phase dysregulation, 
illustrate a clear distinction between the pathogenic mechanisms underlying these 
pathologies (24).  
 
aHUS-associated CFH-CFHRs genomic rearrangements 
The factor H related proteins (FHRs) are relatively minor plasma components with 
concentrations in the range 5 to 50 mg/L, presenting a high degree of similarity with factor 
H. Of particular interest is the almost complete sequence conservation in FHR1 of the C-
terminal region of factor H (25). The genes CFHR3, CFHR1, CFHR4, CFHR2 and CFHR5 
encoding these FHR proteins are located downstream (in that order) and closely linked to 
the CFH gene within a region that shows significant genetic variability and it is 
characterized by the presence of large genomic duplications (ranging in size from 1.2 to 38 
kb) (5). These duplications make the region highly prone to genomic rearrangements 
through gene conversion and non-homologous recombination, which are readily identified 
by MLPA (Multiplex Ligation-dependent Probe Amplification) technologies, CNV (copy 
number variation) microarrays or western blots. Notably, several rearrangements have been 
identified in recent years associated with different pathologies involving complement 
dysregulation, including aHUS (24). 
A very prevalent rearrangement in this region, a true common polymorphism in 
humans, is the deletion of the CFHR1 and CFHR3 genes resulting from a non-homologous 
recombination event between a duplicated region downstream of the CFH and CFHR1 
genes. The deletion of the CFHR1 and CFHR3 genes is included in a single extended 
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CFH-CFHRs haplotype, H4, that associates with lower risk of age-related macular 
degeneration (AMD) (26) and IgA nephropathy (27) and increased risk of systemic lupus 
erythematosus (SLE) (28). Although it is currently unclear whether the deletion of the 
CFHR1 and CFHR3 genes by itself predisposes or protects from aHUS (29, 30), the 
frequency of homozygosity for the CFHR3-CFHR1 deletion is increased among aHUS 
patients as a consequence of the association between complete deficiency of the FHR1 
protein and the generation of anti-factor H autoantibodies (25, 29). This is an intriguing 
association for which there is no clear explanation. Importantly, the anti-factor H 
autoantibodies recognize the C-terminus of factor H (31) and functionally mimic the 
prototypical factor H mutations that are frequently associated with the development of 
aHUS (32). Another relatively frequent rearrangement in the CFH-CFHR region involves 
an unequal crossover between homologous regions in the 3’ ends of CFHR3 and CFHR4 
genes that specifically removes the CFHR1 and CFHR4 genes. This deletion is also found 
in aHUS patients in association with anti-factor H autoantibodies (29, 33). 
Most interesting are the various genomic rearrangements between the 3’ end exons 
of CFH and the homologous regions in CFHR1 or CFHR3, which have been associated 
with aHUS (9, 34). These rearrangements result in the generation of CFH::CFHR1 or 
CFH::CFHR3 hybrid genes that alter the C-terminal region of factor H, further illustrating 
the remarkable correlation between a dysfunctional C-terminal region in factor H and 
aHUS. Similarly, the association of a CFHR1::CFH hybrid gene in which the C-terminal 
exons of FHR1 have been replaced by those in factor H (reversed CFH::CFHR1 hybrid 
gene) suggests that competing the binding of the C-terminal region of factor H to 
substrates that are relevant in aHUS with a protein devoid of complement regulatory 
activity has the same consequences than the C-terminal factor H mutations characteristic of 
aHUS (35). 
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Gain-of-function mutations in factor B and C3 
Factor B and C3 mutations are characteristic of a subgroup of aHUS patients 
showing persistent activation of the alternative pathway (AP) in plasma (15, 16, 36). 
Importantly, while mutations in the complement regulators factor H, MCP and factor I are 
loss-of-function mutations, mutations in factor B or C3 are gain-of-function mutations in 
the sense that they increase formation or stability of the C3 convertase or render it resistant 
to inactivation by the complement regulators (15, 16). These data unequivocally establish 
the critical role that dysregulation of the complement alternative pathway plays in the 
pathogenesis of aHUS and illustrate that complement dysregulation may result from either 
a defect in the regulatory proteins or an abnormally increased activity of the components of 
the C3 convertase of the alternative pathway. 
From a pathogenic point of view it is intriguing that these factor B and C3 gain-of-
function mutations, decreasing C3 plasma levels and causing different degrees of 
hypocomplementemia, are nevertheless associated with aHUS. One possible explanation is 
that increased complement activation caused by gain-of-function mutations, a situation that 
may be similar to that occurring during infection, coincides with an additional aHUS risk 
factor impairing surface protection. In support of this possibility, it has been noted that 
carriers of CFB or C3 gain-of-function mutations that develop aHUS are also carriers of a 
MCP risk haplotype (see below) (15, 36). In the case of the mutations in C3 associated 
with aHUS, different experimental approaches have shown that these mutations alter the 
sensitivity of C3b to inactivation by factor H and MCP and/or change the susceptibility of 
the AP C3 convertase to accelerated decay by factor H and decay accelerating factor (DAF, 
CD55) (16, 36). This data again illustrate that aHUS associated mutations affect 
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preferentially complement regulation on surfaces, which is in contrast with the fluid phase 
dysregulation caused by C3 mutations associated with other glomerulopathies (36, 37). 
 
Therapeutic implications 
 The realization that aHUS is a disorder involving tissue damage caused by 
dysregulated alternative pathway complement activation provided strong support for the 
implementation of aHUS therapies based in the inhibition of the complement terminal 
pathway. Eculizumab, a blocking monoclonal antibody against human C5 that inhibits C5a 
release and terminal complement complex (TCC) formation in general, and membrane 
attack complex (MAC) generation on a cellular target, was first successfully used for 
treatment of paroxysmal nocturnal hemoglobinuria, a hemolytic and thrombotic disorder 
caused by deficiency of glycosylphosphatidylinisotol (GPI)-anchored complement 
regulators CD55 and CD59 on blood cells, which are therefore lysed by MAC formation. 
Eculizumab was successfully tested in aHUS patients, on a compassionate basis, to prevent 
relapses of the disease and recurrences after transplantation (38, 39). Later on, based on the 
excellent results obtained in phase II clinical trials during 2009–2010, eculizumab was 
approved by the US Food and Drugs Administration and the European Medicines Agency 
and has rapidly become the accepted therapy in patients with aHUS (40), both as a rescue 
therapy in acute episodes and as prophylaxis in labile patients and following renal 
transplant (41). 
 
Incomplete penetrance of aHUS in mutation carriers 
The penetrance of disease in carriers of mutations in any of the aHUS-associated 
genes is approximately 50%, indicating that additional genetic and environmental factors 
contribute to disease development in these individuals. In this respect, it is now well 
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documented that concurrence of different genetic risk factors, either combined mutations in 
more than one gene or the combination of mutations and risk polymorphisms, greatly 
influences predisposition to aHUS (10, 15, 42, 43). 
The aHUS-associated polymorphisms are basically limited to three relatively 
frequent CFH and MCP haplotypes, which include both risk and protection factors (44). 
The common CFH haplotype H2 including the common polymorphism Val62Ile has been 
associated with lower risk to aHUS, AMD and DDD. Val62Ile lies within the N-terminal 
region that is essential for factor H regulatory activities. Consistent with the role of 
complement dysregulation in these pathologies it has been shown that the substitution of 
Val for Ile at position 62 increases the complement regulatory of factor H reducing 
activation of the complement alternative pathway. In fact, functional analyses have shown 
that the Val62Ile substitution in factor H increases the affinity for C3b, competing more 
efficiently with factor B for C3b binding in the proconvertase formation and acquiring 
enhanced cofactor activity for the factor-I mediated proteolysis of C3b (45). 
The CFH-H3 and MCPggaac haplotypes are the most relevant aHUS risk 
polymorphisms described thus far. Both haplotypes include SNPs located in the promoter 
region of CFH and MCP that have potential functional implications in the expression of 
factor H and MCP (3, 10). Although additional studies are needed to fully characterize 
these haplotypes functionally, the association of CFH-H3 and MCPggaac with aHUS is 
important because it may help to explain why some individuals are predisposed to aHUS in 
the absence of mutations in the known aHUS associated genes.  It is also increasingly 
recognized that in carriers of mutations in these aHUS-associated genes, the CFH and 
MCP risk haplotypes may be needed for full manifestation of the disease (10, 15, 36, 42). 
A recent collaborative study by the European Working Party on Complement 
Genetics in Renal Diseases in 795 patients with aHUS has identified that 3% of these 
patients carry combined mutations, being combinations involving MCP or CFI mutations 
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(25%) more frequent than those with CFH, C3 or CFB mutations (8%-10%). Furthermore, 
this large study also illustrated that the concomitant presence of CFH and MCP risk 
haplotypes significantly increased disease penetrance in combined mutation carriers, 
further suggesting that genotyping for the CFH and MCP risk haplotypes may help to 
predict risk of developing aHUS in affected carriers of mutations (42). 
Apart from the CFH and MCP polymorphisms, other aHUS-associated 
polymorphisms in FHR proteins include the FHR-1*A/*B variant; possession of the *B 
variant is risk for aHUS (29, 30). Polymorphisms in the CFHR5 gene have also been 
described and associated with risk of aHUS (46). 
Taken together, genetic and functional analyses have established that aHUS 
involves complement alternative pathway dysregulation and develops as a consequence of 
defective protection of cellular surfaces from complement activation. Multiple hits, 
involving plasma and membrane-associated complement regulatory proteins as well as 
complement components, are likely required to cause dysregulation and significantly 
impair protection to host tissues. Environmental factors that activate complement likely 
modulate genetic predisposition and are also very important in aHUS. Infection, 
immunosuppressive drugs, cancer therapies, oral contraceptives, pregnancy and childbirth 
are important factors that trigger attacks of aHUS in some patients. In carriers of multiple 
strong aHUS genetic risk factors the contribution of the environment is probably minor. On 
the other hand, in those with a low genetic predisposition, strong environmental factors 
may still precipitate disease.  
 
Thrombomodulin and other coagulation genes 
The anticoagulant protein thrombomodulin, which functions as a cofactor for 
thrombin to reduce blood coagulation and also regulates factor I-mediated C3b inactivation, 
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has been described associated with aHUS (18). Interestingly, functional analyses of these 
aHUS-associated THBD mutations supported a defect in the complement regulatory 
activities of this protein on cell surfaces, which is consistent with the complement 
dysregulation that characterize aHUS (18). However, it is currently unknown whether the 
anticoagulant activities of thrombomodulin are also disrupted by the aHUS-associated 
mutations and therefore may also be relevant in aHUS. In this regard, a very recent study 
has screened in 36 European-American sporadic aHUS patients, using targeted genomic 
enrichment and massive parallel sequencing, the coding sequences and splice sites in 85 
genes, including all genes in both the complement and coagulation pathways (17). In 
addition to novel variants in various complement genes, the study found deleterious non-
synonymous rare variants in several coagulation genes. PLG, encoding plasminogen, a 
zymogen that is converted into plasmin and plays an important role in fibrinolysis, was the 
most frequently mutated gene (17). Although these data suggest that the coagulation 
pathway and PLG in particular also contribute to aHUS susceptibility, further studies are 
needed to confirm these associations and to determine the role of the coagulation pathway 
in aHUS. 
 
DGKE-aHUS 
Using exome sequencing Lemaire et al. (19) have recently identified recessive 
mutations in DGKE, encoding diacylglycerol kinase-ε, associated with aHUS in 13 
patients from nine kindreds. Disease presentation in these patients occurred very early, 
typically before the age of 1 year, with multiple recurrences often progressing to end stage 
renal disease in the second decade of life. It has been indicated that DGKE mutations may 
explain as much as 27% of cases presenting in the first year of life (19). An independent 
study also found recessive mutations in DGKE in 9 patients from three consanguineous 
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families with MPGN-like syndrome (20). Onset of disease in this second set of patients 
was significantly delayed and none of the patients in the study presented acute episodes 
suggesting aHUS. However, their histology showed features of glomerular 
microangiopathy, supporting that all patients carrying DGKE mutations share a common 
pathogenic mechanism. Although the molecular basis is still unclear, one plausible 
explanation is that loss of DGKE increases signaling through arachidonic acid containing 
diacylglycerol substrates, enhancing protein kinase C activation in endothelial cells, 
platelets and podocytes. As a consequence of this, prothrombotic factors like von 
Willebrand factor, plasminogen activator inhibitor-1, platelet-activating factor and tissue 
factor would be upregulated, leading to a thrombotic phenotype (19). In addition, loss of 
DGKE may result in podocyte damage and impair slit diaphragm function, which could 
explain the heavy proteinuria observed in patients with DGKE mutations (20). 
 Importantly, it was indicated that these individuals do not carry mutations in any of 
the known aHUS candidate complement genes and show no alterations of complement in 
plasma, suggesting that DGKE-associated aHUS represents an alternative mechanism 
leading to thrombotic microangiopathy (19). Although a role for complement 
dysregulation in the development of renal disease in carriers of DGKE mutations seems a 
priori excluded, we have recently identified three DGKE-associated early-onset aHUS 
patients carrying additional mutations in the THBD and C3 genes. Further studies are 
therefore needed to determine whether complement dysregulation may influence the onset 
and severity of the disease phenotype in some carriers of DGKE mutations. 
 
Genotype-phenotype correlations 
The clinical evolution of patients with aHUS, their response to plasma therapies 
and the disease recurrence after kidney transplantation are influenced by the type of 
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mutation involved. In general, patients with CFH, CFI, CFB and C3 mutations have a 
worse prognosis during the episode of aHUS and following months, with rates of mortality 
and end stage renal disease rising to approximately 50%-70% and recurrences occurring in 
more than 50% of them. On the other hand, less than 20% of patients with MCP mutations 
die or develop end stage renal disease, although the risk of recurrence is greater than 70% 
(47).  
Historically, the success of kidney transplants in patients with end stage renal disease 
caused by aHUS has been limited by the high percentage of post-transplant recurrence of 
disease (~50%; graft loss rate: 80%-90%), although results vary based on the type of 
mutation present. CFH mutations are associated with a greater risk of recurrence or graft 
loss following renal transplantation (75%-90%), and high levels of risk are also associated 
with C3 and CFI mutations (40%-80%) (42, 47, 48). Until now, very few transplants have 
been attempted in patients with CFB mutations, but all cases that have been reported to 
date have involved recurrence of aHUS and graft lost. 
Most complement factors involved in aHUS are plasma proteins primarily 
synthesised by the liver and thus patients with mutations of complement genes that code 
for these factors continue to be susceptible to aHUS after renal transplantation, since the 
dysfunctional factors continue to be produced. On the other hand, because MCP is a 
transmembrane protein primarily produced by the kidney, a kidney transplant corrects the 
deficit by producing unaltered MCP in the new kidney. Consequently, more than 80% of 
patients with MCP mutations do not develop recurrent aHUS after transplantation, with a 
similar long-term survival rate to that of patients who receive transplants for other reasons. 
The risk of post-transplant recurrence in patients with THBD mutations or anti-factor H 
antibody mutations is not well understood, although in the case of factor H antibodies, it 
appears that recurrence is related to persistently high antibody titers (31, 47, 48). 
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Among patients with CFH or CFI mutations, the presence of mutations in other 
genes did not modify prognosis; in contrast, 50% of patients with combined MCP mutation 
developed end stage renal disease within 3 years from onset compared with 19% of 
patients with isolated MCP mutation. In general, a similar situation was observed for 
kidney transplant outcomes (42). 
DGKE-aHUS illustrates a very particular subgroup of aHUS patients. As indicated 
above, DGKE-associated aHUS may represent an alternative mechanism involving 
intracellular signaling leading to thrombotic microangiopathy, independent of complement 
dysregulation. Consistent with this idea, two patients with DGKE mutations who received 
plasma treatment or eculizumab, had aHUS recurrences. However, five other patients with 
DGKE mutations underwent eculizumab treatment without evidence of disease recurrence 
(19). On the other side, a total of six aHUS patients with DGKE mutations underwent renal 
transplantation without evidence of aHUS recurrence (19), but one transplanted patient 
with the MPGN-like form showed signs of disease recurrence in the transplanted kidney 
(20). 
 
Concluding remarks 
We have summarized our current understanding of the genetics of aHUS and 
reviewed how the functional analysis of different aHUS-associated genetic variants has 
helped to determine the molecular events that are critical in aHUS pathogenesis. It is now 
well established that mutations or polymorphisms in complement components and 
regulators are strongly associated with aHUS because they specifically impair the capacity 
to protect host cells from complement activation. It is also increasingly appreciated that it 
is the combination of mutations, or mutations and common polymorphisms in CFH and 
MCP, what determines the individual predisposition to aHUS and that this genetic make-
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up influences disease progression, responses to therapies and recurrences after 
transplantation. Based on these genotype-phenotype correlations it is also widely 
recognized that a comprehensive understanding of the genetic component predisposing to 
the pathology and its functional consequences at the protein level is critical to guide 
appropriate diagnostics and effective treatment in aHUS. 
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Figure Legends. 
 
Figure 1, A-C. CFH, MCP and CFI mutations associated with aHUS  
Figure shows a schematic representation with the location of the mutations in the 
protein domains of factor H, MCP and factor I. Mutations that have been demonstrated to 
impair function or decrease expression levels are depicted in bold and underlined. 
Polymorphisms are shown in italics. References are in parenthesis. (*) Rodriguez de 
Cordoba et al. Unpublished Data. 
 
Figure 2. CFB and C3 mutations associated with aHUS 
Figure shows a schematic representation with the location of the mutations in the 
protein domains of factor B and C3. Mutations that have been demonstrated to impair 
function or decrease expression levels are depicted in bold and underlined. Polymorphisms 
are shown in italics. References are in parenthesis. (*) Rodriguez de Cordoba et al. 
Unpublished Data 
 
 
Figure 3. THBD and DGKE mutations associated with aHUS 
Figure shows a schematic representation with the location of the mutations in the 
protein domains of Thrombomodulin and DGK-ε. Mutations that have been demonstrated 
to impair function or decrease expression levels are depicted in bold and underlined. 
References are in parenthesis. (*) Rodriguez de Cordoba et al. Unpublished Data 
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